A recent study suggests that spironolactone, a common blood pressure medication, may significantly help stroke survivors achieve critical health targets.
A new study, known as the REDUCE trial, indicates that spironolactone, a low-cost medication often referred to as a water pill, could assist stroke survivors in managing elevated blood pressure levels that persist despite treatment. The findings were presented at the American Heart Association’s Scientific Sessions, held from November 6 to 9, 2026, in Chicago.
In the trial, participants were divided into two groups. One group received spironolactone in addition to their regular post-stroke treatment, while the other group continued with standard care. Researchers monitored the participants’ blood pressure at home over a six-month period to assess the impact of the medication.
After three months, the results showed that the average top blood pressure reading for those taking spironolactone was nearly eight points lower than that of the control group—126 mmHg compared to 133 mmHg. Furthermore, a greater percentage of patients on spironolactone achieved the recommended blood pressure target of less than 130/80 mmHg, with 52% meeting this goal compared to only 30% in the usual care group.
“Lowering blood pressure is the most important step in preventing another stroke, yet many survivors struggle to reach recommended blood pressure targets after a stroke,” said Dr. Jordana Cohen, co-lead author of the study and an associate professor of medicine and epidemiology at the University of Pennsylvania. “When spironolactone was added to post-stroke care, we saw a meaningful drop in blood pressure that may lower the risk of future strokes and heart attacks.”
Dr. Alfred Joshua, a board-certified emergency physician based in California and a former chief medical officer who was not involved in the research, expressed cautious optimism regarding the findings. He noted that while the study demonstrated a reduction in blood pressure, it does not yet confirm that spironolactone prevents subsequent strokes. “We already know that controlling blood pressure lowers the risk of another stroke,” Joshua explained. “This study measured blood pressure, so whether adding spironolactone leads to fewer repeat strokes is still an open question.”
Spironolactone functions by aiding the body in eliminating excess salt and water, which can contribute to lower blood pressure levels. It also helps the body retain potassium, necessitating regular monitoring of potassium levels for patients taking the medication, as highlighted in the drug’s prescribing information.
Joshua cautioned that elevated potassium levels pose a significant safety concern, as they can develop without noticeable symptoms. This risk may be heightened for individuals with kidney issues or those taking certain medications or potassium supplements. Additionally, he noted that spironolactone can lower blood pressure to the extent that it may cause dizziness.
“If your blood pressure remains high after a stroke, consider bringing your home readings to your clinician and discussing whether this medication is a suitable option,” Joshua advised.
The REDUCE trial concluded early, involving 160 participants instead of the initially planned 200. Researchers also noted that approximately 15% of participants did not have blood pressure readings available at the three-month follow-up. Those taking spironolactone were also on slightly more blood pressure medications overall compared to those receiving standard care.
Importantly, the study was not designed to determine whether spironolactone directly prevents subsequent strokes or heart attacks. Researchers emphasized the need for larger and longer-term studies to address this question adequately.
For more information, please refer to the findings presented at the American Heart Association’s Scientific Sessions.
According to Fox News Digital, the implications of these findings could significantly impact the management of blood pressure in stroke survivors.

